Goel N, Ulrich D T, St Clair E W, Fleming J A, Lynch D H, Seldin M F
Duke University Medical Center, Durham, NC 27710, USA.
Arthritis Rheum. 1995 Dec;38(12):1738-43. doi: 10.1002/art.1780381206.
To determine whether elevated soluble Fas/APO-1 (sFas/APO-1) levels are associated with either autoimmune disease or evidence of flares in autoimmune disease.
Thirty-seven serum samples were retrospectively obtained from normal controls and patients with laboratory evidence of autoimmune disease activity. These samples were assayed for sFas/APO-1 levels by an enzyme-linked immunosorbent assay, and hospital medical records were retrospectively reviewed for clinical and laboratory characteristics of the patients.
Soluble Fas/APO-1 levels did not correlate with clinical diagnoses or laboratory abnormalities. The mean and range of sFas/APO-1 levels were similar in systemic lupus erythematosus patients (including those with active disease), patients with other autoimmune diseases, and normal controls.
These data strongly suggest that measurement of sFas/APO-1 levels is unlikely to hold clinical value or play a role in the pathogenesis of autoimmune disease.
确定可溶性Fas/APO-1（sFas/APO-1）水平升高是否与自身免疫性疾病或自身免疫性疾病发作的证据相关。
回顾性收集37份血清样本，来自正常对照者以及有实验室证据表明存在自身免疫性疾病活动的患者。通过酶联免疫吸附测定法检测这些样本的sFas/APO-1水平，并回顾性查阅医院病历以了解患者的临床和实验室特征。
可溶性Fas/APO-1水平与临床诊断或实验室异常无关。系统性红斑狼疮患者（包括那些患有活动性疾病的患者）、其他自身免疫性疾病患者和正常对照者的sFas/APO-1水平均值及范围相似。
这些数据强烈表明，检测sFas/APO-1水平不太可能具有临床价值，也不太可能在自身免疫性疾病的发病机制中发挥作用。
